JP2005525322A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005525322A5 JP2005525322A5 JP2003564040A JP2003564040A JP2005525322A5 JP 2005525322 A5 JP2005525322 A5 JP 2005525322A5 JP 2003564040 A JP2003564040 A JP 2003564040A JP 2003564040 A JP2003564040 A JP 2003564040A JP 2005525322 A5 JP2005525322 A5 JP 2005525322A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- general formula
- different
- methyl
- same
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 13
- -1 hydroxy, methyl Chemical group 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 239000011737 fluorine Substances 0.000 claims 4
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 150000001450 anions Chemical class 0.000 claims 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 3
- 229940006460 bromide ion Drugs 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 2
- 239000000812 cholinergic antagonist Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 230000001225 therapeutic Effects 0.000 claims 2
- 208000006673 Asthma Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 claims 1
- 229960001334 Corticosteroids Drugs 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 102100000918 MAPK14 Human genes 0.000 claims 1
- HVAUUPRFYPCOCA-AREMUKBSSA-O PAF Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP(O)(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-O 0.000 claims 1
- 206010040741 Sinus bradycardia Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 210000003708 Urethra Anatomy 0.000 claims 1
- 239000000808 adrenergic beta-agonist Substances 0.000 claims 1
- 230000003042 antagnostic Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000000043 antiallergic agent Substances 0.000 claims 1
- 230000003454 betamimetic Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 claims 1
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 claims 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims 1
- 230000002496 gastric Effects 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- 230000003287 optical Effects 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000033764 rhythmic process Effects 0.000 claims 1
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 claims 1
- 230000001515 vagal Effects 0.000 claims 1
Claims (12)
- 一般式1の化合物。
Aは
X-は単一の負の電荷を有する陰イオンを表し、
Rはヒドロキシ、メチル、ヒドロキシメチル、エチル、-CF3、CHF2又はフッ素を表し、 R1及びR2は同じであっても、また異なっていてもよく、これらは必要によりC3-C6-シクロアルキル、ヒドロキシ又はハロゲンにより置換されていてもよいC1-C5-アルキルを表し、又は
R1及びR2は一緒になって-C3-C5-アルキレン-ブリッジを表し、
R3、R4、R3'及びR4'は同じであっても、また異なっていてもよく、これらは水素、-C1-C4-アルキル、-C1-C4-アルキルオキシ、ヒドロキシ、-CF3、-CHF2、CN、NO2又はハロゲンを表す〕 - 必要により個々の光学異性体、個々の鏡像体の混合物又はこれらのラセミ体の形態の、請求項1から4のいずれか1項記載の一般式1の化合物。
- 請求項1から5のいずれか1項記載の一般式1の化合物を含有する、抗コリン作用薬が治療上の利益を発生し得る疾患の治療のための医薬組成物。
- 抗コリン作用薬が治療上の利益を発生し得る疾患の治療のための医薬組成物を調製するための請求項1から5のいずれか1項記載の一般式1の化合物の使用。
- 喘息、COPD、迷走神経誘発洞徐脈、心臓律動障害、胃腸道中の痙攣、尿道中の痙攣及び月経痛の治療のための医薬組成物を調製するための請求項1から5のいずれか1項記載の一般式1の化合物の使用。
- 必要により通常の賦形剤及び/又は担体と組み合わせて活性物質として請求項1から5のいずれか1項記載の一般式1の一種以上の化合物又はこれらの生理学上許される塩を含むことを特徴とする医薬製剤。
- 医薬製剤が、式1の一種以上の化合物に加えて、ベータ擬態、抗アレルギー薬、PAFアンタゴニスト、PDE IVインヒビター、ロイコトリエンアンタゴニスト、p38キナーゼインヒビター、EGFRキナーゼインヒビター及びコルチコステロイドの中から選ばれる少なくとも一種のその他の活性物質を含むことを特徴とする、請求項9記載の医薬製剤。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10203753A DE10203753A1 (de) | 2002-01-31 | 2002-01-31 | Neue Xanthencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
PCT/EP2003/000532 WO2003064417A1 (de) | 2002-01-31 | 2003-01-21 | Xanthencarbonsäureester des tropenols und scopins als m3-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005525322A JP2005525322A (ja) | 2005-08-25 |
JP2005525322A5 true JP2005525322A5 (ja) | 2006-03-09 |
JP4554936B2 JP4554936B2 (ja) | 2010-09-29 |
Family
ID=27588164
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003564040A Expired - Lifetime JP4554936B2 (ja) | 2002-01-31 | 2003-01-21 | M3アンタゴニストとしてのトロペノール及びスコピンのキサンテンカルボン酸エステル、その製造方法及び薬物としてのその使用 |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1472249B1 (ja) |
JP (1) | JP4554936B2 (ja) |
AT (1) | ATE335738T1 (ja) |
CA (1) | CA2471578C (ja) |
DE (2) | DE10203753A1 (ja) |
ES (1) | ES2269977T3 (ja) |
WO (1) | WO2003064417A1 (ja) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10230751A1 (de) * | 2002-07-09 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und EGFR-Kinase-Hemmern |
US7056916B2 (en) | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
ATE526967T1 (de) * | 2003-07-31 | 2011-10-15 | Boehringer Ingelheim Int | Medikamente für inhalationen enthaltend ein anticholinergikum und ein betamimetikum |
DE102004001607A1 (de) * | 2004-01-09 | 2005-08-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkombinationen auf der Basis von Scopin- oder Tropensäureestern mit EGFR-Kinase-Hemmern |
US7507745B2 (en) | 2004-02-20 | 2009-03-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions based on fluorenecarboxylic acid esters and soluble TNF receptor fusion proteins |
CA2552903A1 (en) * | 2004-02-20 | 2005-09-01 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions based on anticholinergics and pegsunercept |
DE102004016179A1 (de) * | 2004-03-30 | 2005-10-20 | Boehringer Ingelheim Pharma | Verbindungen zur Behandlung von proliferativen Prozessen |
US7220742B2 (en) | 2004-05-14 | 2007-05-22 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
DE602004020337D1 (de) * | 2004-08-11 | 2009-05-14 | Boehringer Ingelheim Pharma | Anticholinergika enthaltende Arzneimittel zur Behandlung von Krankheiten der ableitenden Harnwege |
CA2597942A1 (en) * | 2005-02-16 | 2006-08-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions comprising anticholinergics and etiprednol |
WO2006094924A2 (en) * | 2005-03-09 | 2006-09-14 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions based on anticholinergics and pde 5-inhibitors |
JP2008542332A (ja) * | 2005-05-31 | 2008-11-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器疾患治療用新規医薬組成物 |
DE102005030733A1 (de) | 2005-07-01 | 2007-01-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff |
KR101360803B1 (ko) | 2005-08-15 | 2014-02-11 | 베링거 인겔하임 인터내셔날 게엠베하 | 베타모방제의 제조방법 |
US7423146B2 (en) | 2005-11-09 | 2008-09-09 | Boehringer Ingelheim International Gmbh | Process for the manufacturing of pharmaceutically active 3,1-benzoxazine-2-ones |
WO2008017637A1 (de) | 2006-08-07 | 2008-02-14 | Boehringer Ingelheim International Gmbh | Arzneimittelkombinationen zur behandlung von atemwegserkrankungen |
UY30550A1 (es) | 2006-08-22 | 2008-03-31 | Boehringer Ingelheim Int | Nuevos beta-agonistas enantioméricamente puros, procedimientos para su preparacion y su uso como medicamentos |
EP2011538B1 (en) | 2007-07-06 | 2016-02-17 | Vectura Delivery Devices Limited | Inhaler |
WO2009010492A2 (en) * | 2007-07-18 | 2009-01-22 | Boehringer Ingelheim International Gmbh | Combinations comprising telmisartan and an anticholinergic such as tiotropium or a glycopyrronium salt for the treatment of respiratory diseases such as copd or asthma |
EP2082772A1 (en) | 2008-01-24 | 2009-07-29 | Vectura Delivery Devices Limited | Inhaler |
EP2082768A1 (en) | 2008-01-24 | 2009-07-29 | Vectura Delivery Devices Limited | Inhaler |
EP2082767A1 (en) | 2008-01-24 | 2009-07-29 | Vectura Delivery Devices Limited | Inhaler |
EP2082766A1 (en) | 2008-01-24 | 2009-07-29 | Vectura Delivery Devices Limited | Blister Strip Coil Forming |
EP2082771A1 (en) | 2008-01-24 | 2009-07-29 | Vectura Delivery Devices Limited | Inhaler |
EP2093219A1 (de) | 2008-02-22 | 2009-08-26 | Boehringer Ingelheim International Gmbh | Kristalline, enantiomerenreine Salzform eines Betamimetikums und dessen Verwendung als Arzneimittel |
GB0918450D0 (en) | 2009-10-21 | 2009-12-09 | Innovata Ltd | Composition |
PT3691620T (pt) | 2017-10-05 | 2022-10-06 | Fulcrum Therapeutics Inc | Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4108393A1 (de) * | 1991-03-15 | 1992-09-17 | Boehringer Ingelheim Kg | Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln |
ES2165768B1 (es) * | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
DE10050994A1 (de) * | 2000-10-14 | 2002-04-18 | Boehringer Ingelheim Pharma | Neue als Arneimittel einsetzbare Anticholinergika sowie Verfahren zu deren Herstellung |
-
2002
- 2002-01-31 DE DE10203753A patent/DE10203753A1/de not_active Withdrawn
-
2003
- 2003-01-21 WO PCT/EP2003/000532 patent/WO2003064417A1/de active IP Right Grant
- 2003-01-21 AT AT03704440T patent/ATE335738T1/de active
- 2003-01-21 EP EP03704440A patent/EP1472249B1/de not_active Expired - Lifetime
- 2003-01-21 ES ES03704440T patent/ES2269977T3/es not_active Expired - Lifetime
- 2003-01-21 CA CA2471578A patent/CA2471578C/en not_active Expired - Fee Related
- 2003-01-21 DE DE50304569T patent/DE50304569D1/de not_active Expired - Lifetime
- 2003-01-21 JP JP2003564040A patent/JP4554936B2/ja not_active Expired - Lifetime
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005516067A5 (ja) | ||
JP2005525322A5 (ja) | ||
JP2005525323A5 (ja) | ||
CA2472149A1 (en) | New fluorenecarboxylic acid esters, process for the manufacture thereof and use thereof as medicaments | |
JP2004511556A5 (ja) | ||
CA2471578A1 (en) | Xanthene-carboxylic acid esters of tropenol and scopine as m3 antagonists, method for producing the same and use thereof as medicaments | |
RU2004126441A (ru) | Новые антихолинергические средства, способ их получения, а также их применение в качестве лекарственных средств | |
US9815832B2 (en) | Azabenzimidazole compounds | |
JP2009542613A5 (ja) | ||
JP2009534368A5 (ja) | ||
RU2012103487A (ru) | Ингибирующие jak соединения на основе пиразолопиримидина и способы | |
JP2020510010A5 (ja) | ||
JP2021105002A5 (ja) | ||
CN102292340A (zh) | 用作pde9 抑制剂的氨基-杂环类化合物 | |
JP2008509187A5 (ja) | ||
JP2003504368A5 (ja) | ||
JP2006151984A5 (ja) | ||
JP2003532731A5 (ja) | ||
JP2005519908A5 (ja) | ||
JP2007522162A5 (ja) | ||
JP2010513434A5 (ja) | ||
JP2003529596A5 (ja) | ||
JP2007529444A5 (ja) | ||
JP2005511698A5 (ja) | ||
JP2009544659A (ja) | M3アンタゴニストとしてのキヌクリジン誘導体 |